1318 results about "Aqueous suspension" patented technology

Submicron particles of water-insoluble compounds, particularly drugs, are prepared by simultaneously stabilizing microparticulate suspensions of same with surface modifier molecules by rapid expansion into an aqueous medium from a compressed solution of the compound and surface modifiers in a liquefied gas and optionally homogenizing the aqueous suspension thus formed with a high pressure homogenizer.

The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and / or lower airway passages and / or lungs, e.g., allergic rhinitis and asthma is disclosed.

An aqueous suspension of titanium dioxide, polymethylmethacrylate and Vitamin E oil is used to mark a location wherein a skin biopsy has been taken to enable subsequent identification of the biopsy location under ultraviolet light. The location is advantageously treated with Vitamin E oil on a daily basis subsequently extend the fluorescing life of the applied titanium dioxide.

The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w / v) to about 90% (w / v) of the drug in solution, as dissolved free drug and as dissolved drug / cyclodextrin complex(es), and a solid phase of from about 10% (w / v) to about 99.9% (w / v) of the drug as solid drug / cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug / cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist. Further, the invention provides a method for treating a condition of the posterior segment and / or anterior segment of the eye comprising applying to the eye surface, in an amount which delivers to said segment or segments a therapeutically effective amount of a drug suitable for treating said condition, an ophthalmic composition which is as defined above. Nasal compositions and methods and ophthalmic and nasal compositions in powder form are also provided.

A liposomal aqueous dispersion and method of making the liposomal aqueous dispersion is useful for encapsulation of drugs. The liposomal aqueous dispersion comprises: an aqueous suspension medium; multilamellar liposomes comprising an anionic phospholipid and cholesterol as essential components; neutral phospholipid in a mole ratio of 0 to 40% based on the total amount of said multilamellar liposomes; and a cation moiety-containing water-soluble drug, wherein the electrolyte concentration of said aqueous suspension medium is not more than 40 mM.

The present invention relates to a delivery system which includes a bioactive drug or cosmetic substance presented in the form of submicron oil spheres alone, or drugs or cosmetic substances in a combination with the oil spheres in an aqueous suspension or emulsion. Optionally, a skin penetration enhancer may be included in such formulations. Such preparations achieve improved bioavailability and exert larger pharmacological effects than an equivalent dose of the drug or cosmetic formulated in conventional creams, lotions or oleaginous bases.

The present invention relates to a method of preparing microfibrillar polysaccharide comprising treating a polysaccharide in an aqueous suspension comprising an oxidant and at least one transition metal, mechanically delaminating said polysaccharide such that microfibrillar polysaccharide is formed. The invention also relates to microfibrillar polysaccharide obtainable by the method.

Topical aqueous suspension compositions of sparingly soluble ophthalmic drugs are disclosed. The compositions comprise a combination of a poloxamer or meroxapol surfactant and a glycol tonicity-adjusting agent such as propylene glycol.

This is a method of filtration of a liquid comprising steps of sequential filtration of said liquid through at least one deep bed medium producing at least one first filtrate followed by at least one membrane medium filtration producing at least one second filtrate, wherein said membrane medium is at least periodically within said deep bed media Many types of deep bed and membrane media can be used. The domain of using contact clarification (direct filtration) can be expanded towards greater solids concentration. Operation and backwash, is simplified, continuous filtration becomes possible. Water can be water from natural source water, process water, wastewater, aqueous or non-aqueous suspensions, emulsions, solutions. Treatment can include mechanical interception of suspended particles, chemical, physical chemical, electrochemical, and biological processes. In water and wastewater processing, control over suspended solids, BOD, COD, nitrogen and phosphorus compounds, bacteria and viruses, heavy metals, color, and other constituents can be dramatically improved as compared to conventional processes. The method can be accommodated in new and modified existing treatment systems.

A method for making hydrophobic non-aggregated colloidal silica comprising reacting an aqueous suspension of a hydrophilic non-aggregated colloidal silica having an average particle diameter greater than about 4 nm with a silicon compound at a pH less than about pH 4 in the presence of a sufficient quantity of a water-miscible organic solvent to facilitate contact of the hydrophilic non-aggregated colloidal silica with the silicon compound. The method is conducted at a temperature within a range of about 20 DEG C. to 250 DEG C. for a period of time sufficient to form a hydrophobic non-aggregated colloidal silica. The hydrophobic non-aggregated colloidal silicas prepared by the present method are particularly useful as fillers in silicone compositions such as adhesives, rubbers, and sealants.

A process for the production of paper from an aqueous suspension containing cellulosic fibers, and optional fillers, which comprises draining the suspension to obtain a paper web and subjecting the obtained paper web to impulse pressing by passage through at least one press nip having at least one heated roll which is in contact with the web and heated to a temperature above 100° C., wherein a chemical system comprising a polymer component and micro- or nanoparticles are added to the suspension or the paper web before the paper web passes the press nip of the impulse unit.

A method of producing microparticles and nanoparticles of a solute via the extraction of solvent, having the solute dissolved therein, from an emulsion using a supercritical fluid. The solute to be precipitated is dissolved in the solvent to form a solution, and the solution is dispersed in an immiscible or partially miscible liquid to form an emulsion. The particles are produced via the extraction of the solvent from the emulsion using the supercritical fluid. The process can produce an aqueous suspension of particles that are substantially insoluble in water, and the solvents used in the process to form the emulsion initially can be recovered and recycled.

The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w / v) to about 90% (w / v) of the drug in solution, as dissolved free drug and as dissolved drug / cyclodextrin complex(es), and a solid phase of from about 10% (w / v) to about 99.9% (w / v) of the drug as solid drug / cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug / cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist. Further, the invention provides a method for treating a condition of the posterior segment and / or anterior segment of the eye comprising applying to the eye surface, in an amount which delivers to said segment or segments a therapeutically effective amount of a drug suitable for treating said condition, an ophthalmic composition which is as defined above. Nasal compositions and methods and ophthalmic and nasal compositions in powder form are also provided.

Described is a stable initial impact and continuous impact fragrance and / or benefit agent-imparting aqueous suspension of microencapsulated fragrance and / or benefit agent, e.g., malodour counteractant suspended in a non-confined fragrance-containing and / or benefit agent-containing liquid phase oil-in-water emulsion. On storage, the viscosity of the suspension undergoes a minimal increase over an extended period of time thereby avoiding undesirable agitation resistance during the blending of the suspension with other materials. The suspension is thus useful for imparting a benefit or an aroma to a consumable material such as a liquid anionic, cationic, non-ionic or zwitterionic detergent, a shampoo, a bodywash, liquid soaps, hair conditioners, skin lotions, anti-perspirants, deodorants or liquid fabric softener and / or conditioner compositions. Also described is a process for preparing such stable suspensions and apparatus for carrying out such process.

A method of treating a kaolin particulate material to improve its properties by removal of impurities which includes the steps of:(a) producing a dispersed aqueous suspension of a kaolin particulate material containing at least 0.1% by weight, based on the dry weight of the kaolin particulate material, of separable impurity by adding a dispersing agent to the kaolin particulate material to deflocculate solid particles of the material in the suspension;(b) conditioning the suspension prior to adding selective flocculation polymer thereto by allowing the suspension to age for a period of at least 30 minutes and optionally by adding one or more conditioning chemicals thereto;(c) adjusting the pH of the suspension to be at least about 9.5;(d) adding to the suspension at a pH of at least about 9.5 a selective flocculation polymer which facilitates separation of the separable impurity from the kaolin by flocculating the kaolin and allowing the separable impurity to be or remain deflocculated;(e) allowing the suspension at a pH of at least about 9.5 in a selective flocculation separator to separate into layers comprising a flocculated product layer and a deflocculated impurity layer containing the separable impurity; and(f) extracting the separated layers from the separator.

Nanocomposite copper-ceria catalysts are provided, which comprise copper oxide nanoparticles, copper nanoparticles, or a mixture thereof combined with ceria nanoparticles. Methods for making such catalysts are also provided, which involve the steps of (i) combining ceria nanoparticles in an aqueous suspension with copper 2,4-pentanedionate to form a slurry; (ii) heating the slurry formed in step (i) under an inert gas atmosphere or an oxygen-argon atmosphere, at a temperature and for a time sufficient to cause decomposition of the copper 2,4-pentanedionate to form copper nanoparticles and / or copper oxide nanoparticles that are combined with the ceria nanoparticles; and (iii) optionally, subjecting the product formed in step (ii) to a heat treatment process under conditions effective to convert at least some of the copper nanoparticles to copper oxide nanoparticles. The nanocomposite copper-ceria catalysts are useful for low-temperature and near-ambient temperature catalysis, such as the oxidation of carbon monoxide, the reduction of nitric oxide and the conversion of hydrocarbons. The nanocomposite copper-ceria catalysts have a variety of potential applications, for example, in vehicle exhaust emission systems of automobiles and diesel engines, cold starting of automobile engine, fuel cells, lasers, hydrocarbon conversion reactors, air filters for the conversion of carbon monoxide and / or indoor volatile organic compounds, and smoking articles.

The present invention concerns methods of making physically stable aqueous suspensions of sparingly soluble to insoluble in water, active pharmaceuticals. More particularly, the invention provides an aqueous pharmaceutical suspension composition comprising an active pharmaceutical component which is sparingly soluble to insoluble in water; a water soluble, low viscosity grade cellulose polymer with a viscosity range of 3 mPa·s to 50 mPa·s as a surfactant; a suspending agent; and water.

The present disclosure relates to a coating composition for use in producing a coating on paper and other substrates comprising an aqueous suspension of a particulate pigment together with a binder, wherein the particulate pigment comprises a mixture of: a first pigment component comprising particulate ground calcium carbonate (GCC) having a particle size distribution (psd) steepness factor ranging from about 30 to about 45; and a second pigment component comprising particulate precipitated calcium carbonate (PCC) having a psd steepness factor ranging from about 55 to about 75. The particulate pigment may optionally further include a particulate kaolin clay.

An oil-based drilling fluid having a polymer latex capable of providing a deformable latex film on at least a portion of a subterranean sand formation has been discovered to inhibit or control fluid loss and act as a sealing agent when used to drill in sand formations for hydrocarbon recovery operations. Typically, the polymer latex is an aqueous suspension of particles formed by emulsion polymerization that is in turn emulsified into a hydrocarbon base fluid. The polymer particles of suitable size precipitate onto the pores of a subterranean sand formation to at least partial seal the formation with a deformable polymer film.

The invention relates to a method of preventing gel formation of a hydrophobic peptides by contacting the hydrophobic peptide with a counter-ion in an amount and at a molar ratio with the peptide that are sufficient to provide a fluid, milky microcrystalline aqueous suspension of the peptide without formation of a gel. The invention also relates to a fluid, milky microcrystalline aqueous suspension of a hydrophobic peptide and a counter-ion in water, wherein the peptide and counter-ion are present in amounts and at a molar ratio sufficient to form, upon mixing, the suspension without formation of a gel.

A coated article (e.g., 244) and a method for preparing a coating (e.g., 400) for a metallic substrate (402) are described. In one embodiment, the method includes preparing a ceramic powder comprising particles of a ceramic material (404) doped with a catalyst species (406). The method also includes adding metal particles (408) and the ceramic powder to a fluid to form a fluid suspension effective to maintain the catalyst species dispersed therein, and then applying the fluid suspension to the metallic substrate to form the coating thereon. In another embodiment, an aqueous suspension of undoped ceramic particles (316) may be combined with a fluid suspension of metallic particles to form the coating.

The invention relates to a method of producing a laminate paper product comprising at least two layers, said method comprising (i) providing an aqueous suspension comprising cellulosic fibers (ii) adding to the suspension microfibrillar polysaccharide in an amount to yield from about 0.05 to about 50 wt % based on the weight of the cellulosic fibers (iii) dewatering the obtained suspension and forming a first layer having a density from about 150 to about 500 kg / m3 of said laminate paper product. The invention also relates to a method comprising (i) providing an aqueous suspension comprising cellulosic fibers (ii) adding to the suspension microfibrillar polysaccharide in an amount to yield from about 0.05 to about 50 wt % based on the weight of the cellulosic fibers (iii) dewatering the obtained suspension and forming at least a first and a second layer of said laminate whereby at least one of said at least first and second layer is formed from an aqueous suspension obtained in step (ii) containing microfibrillar polysaccharide; and joining said layers in such way that the laminate product obtains a density from about 150 to about 800 kg / m3. The invention also relates to a laminate paper product which can be obtained by the method and the use thereof.

A method and an apparatus for preparing a substantially clear aqueous solution containing magnesium bicarbonate are disclosed. One method of preparing a substantially clear aqueous solution containing magnesium bicarbonate, includes contacting, with species resulting from the dissolution of carbon dioxide in water, an aqueous suspension of magnesium carbonate, at suitable conditions of pressure and temperature, so as to obtain an aqueous solution of magnesium bicarbonate and controlling the pH of the said solution so that, after reaction of the said species with the magnesium carbonate, the final pH falls within a range of from about 8.0 to about 8.8. One apparatus suitable for preparing an aqueous solution of magnesium bicarbonate, comprises means for contacting, with species resulting from the dissolution of carbon dioxide in water, a suspension of powdered magnesium carbonate in water so as to form an aqueous solution of magnesium bicarbonate and means for controlling the pH of the solution between about 7 and about 9 by adjusting the amount of at least one of the said species and said powdered magnesium carbonate that is contacted with the other.

Described herein are systems, methods, and apparatuses for aggregating microorganism in an aqueous suspension. In particular, are systems, methods, and apparatuses that apply an electrical field and / or acoustic energy to an aqueous suspension comprising microorganisms as the aqueous suspension follows a flow path to cause aggregation of the microorganisms. The electrical field may be continuous or pulsed. In some embodiments, the flow path for the aqueous suspension may vary.

A process for producing paper webs having a pattern formed into the web is disclosed. The pattern is formed during formation of the web and is made by varying the basis weight of the web. The paper web is produced by depositing an aqueous suspension of fibers between two forming surfaces. One or both of the forming surfaces include lower permeability areas that create lower basis weight areas in the web. The lower permeability areas are contained in the forming surface according to a particular pattern. For instance, the lower permeability areas can be formed into a drainage roll sleeve contained on a drainage roll which contacts a forming surface. The drainage roll can be a forming roll or a breast roll.

A device for sustained delivery of a poorly water soluble drug is described. A drug reservoir within the device, when in operation, contains an aqueous suspension of the drug mixed with a suspension of an excipient that, in one embodiment, generates acidic groups for a sustained period of time to maintain a desired pH in the aqueous suspension that in turn provides a constant concentration of a soluble form of the drug.

An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.